Synthesis of 8H-3A-aza-cyclopenta [A ]indenes and 5,10-dihydropyrrolo[1,2-B]isoquinolines derivatives and their use as antitumor therapeutic agents
AssigneeAcademia Sinica
InventorsTsann-Long Su, Ting-Chao Chou
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a series of bis(hydroxymethyl) and its bis(carbamate) of 8H-3a-azacyclopenta[a]indene-1-yl and 5,10-dihydropyrrolo-[1,2-b]isoquinolines derivatives (Formula I-Formula IV) as DNA di-alkylating agents. The preliminary antitumor studies indicated that compounds disclosed herein could exhibit potent cytotoxicity in vitro and antitumor therapeutic efficacy in human tumor xenografts and could have little or no cross-resistance to either Taxol or Vinblastine. The results demonstrated that compounds disclosed herein possess potent antitumor therapeutic efficacy and are expected to have potential for clinical applications.
Claims21
A compound of formula I, II, III, or IV:
- and pharmaceutically acceptable salts and mixtures thereof,
- wherein:
- R1 is chosen from hydrogen, a C1-C5 linear or branched alkyl group, an aryl, and a benzyl, which may be unsubstituted or substituted;
- R2, R3, R4 and R5 are independently chosen from hydrogen, C1-C6 alkyl, ORa, halo, cyano, nitro, NH2, NHRb, and N(Rb)2, wherein Ra is chosen from hydrogen and C1-C10 alkyl, and Rb is chosen from hydrogen and C1-C10 alkyl;
- and
- R6 is chosen from a saturated or unsaturated, linear or branched, C1-C5 alkyl group, an unsubstituted or substituted phenyl group, and an unsubstitued or substituted benzyl group,
- and further wherein:
- when the C1-C5 linear or branched alkyl group is substituted, one or more substituents are independently chosen from halogen, hydroxy, alkoxy, lower alkyl, lower alkenyl, and lower alkynyl;
- and
- when the aryl, the benzyl, or the phenyl group is substituted, one or more substituents are independently chosen from C1-C6 alkyl, ORa, halo, cyano, nitro, NH2, wherein Ra is as defined above.
The method of dam 16, wherein the compound is administered in conjunction with radiation therapy, immunotherapy, monoclonal antibody therapy, hormonal therapy, chemotherapy using other agents, and/or surgery.
Dependencies are inferred from the claim text.